Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?

PURPOSE OF REVIEW: The aim of this review is to summarize the available clinical efficacy and safety data related to the most studied and used lipid-lowering nutraceuticals. RECENT FINDINGS: A growing number of meta-analyses of randomized clinical trials supports the effectiveness and tolerability o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicero, Arrigo F. G., Fogacci, Federica, Stoian, Anca Pantea, Vrablik, Michal, Al Rasadi, Khalid, Banach, Maciej, Toth, Peter P., Rizzo, Manfredi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Nonstatin Drugs (M. Vrablik, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332568/
https://www.ncbi.nlm.nih.gov/pubmed/34345932
http://dx.doi.org/10.1007/s11883-021-00955-y
_version_ 1783732917839593472
author Cicero, Arrigo F. G.
Fogacci, Federica
Stoian, Anca Pantea
Vrablik, Michal
Al Rasadi, Khalid
Banach, Maciej
Toth, Peter P.
Rizzo, Manfredi
author_facet Cicero, Arrigo F. G.
Fogacci, Federica
Stoian, Anca Pantea
Vrablik, Michal
Al Rasadi, Khalid
Banach, Maciej
Toth, Peter P.
Rizzo, Manfredi
author_sort Cicero, Arrigo F. G.
collection PubMed
description PURPOSE OF REVIEW: The aim of this review is to summarize the available clinical efficacy and safety data related to the most studied and used lipid-lowering nutraceuticals. RECENT FINDINGS: A growing number of meta-analyses of randomized clinical trials supports the effectiveness and tolerability of some lipid-lowering nutraceuticals such as red yeast rice, plant sterols and stanols, soluble fibers, berberine, artichoke extracts, bergamot polyphenol fraction, garlic, green tea, and spiruline. No significant safety concern has been raised for the use of such products. Association of more lipid-lowering nutraceuticals and of some nutraceuticals with lipid-lowering drugs has been tested as well. SUMMARY: Current evidence suggests that some clinically tested lipid-lowering nutraceuticals could be safely used to improve plasma lipid levels in subjects affected by mild-to-moderate dyslipidaemia with low cardiovascular risk.
format Online
Article
Text
id pubmed-8332568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-83325682021-08-20 Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? Cicero, Arrigo F. G. Fogacci, Federica Stoian, Anca Pantea Vrablik, Michal Al Rasadi, Khalid Banach, Maciej Toth, Peter P. Rizzo, Manfredi Curr Atheroscler Rep Nonstatin Drugs (M. Vrablik, Section Editors) PURPOSE OF REVIEW: The aim of this review is to summarize the available clinical efficacy and safety data related to the most studied and used lipid-lowering nutraceuticals. RECENT FINDINGS: A growing number of meta-analyses of randomized clinical trials supports the effectiveness and tolerability of some lipid-lowering nutraceuticals such as red yeast rice, plant sterols and stanols, soluble fibers, berberine, artichoke extracts, bergamot polyphenol fraction, garlic, green tea, and spiruline. No significant safety concern has been raised for the use of such products. Association of more lipid-lowering nutraceuticals and of some nutraceuticals with lipid-lowering drugs has been tested as well. SUMMARY: Current evidence suggests that some clinically tested lipid-lowering nutraceuticals could be safely used to improve plasma lipid levels in subjects affected by mild-to-moderate dyslipidaemia with low cardiovascular risk. Springer US 2021-08-04 2021 /pmc/articles/PMC8332568/ /pubmed/34345932 http://dx.doi.org/10.1007/s11883-021-00955-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Nonstatin Drugs (M. Vrablik, Section Editors)
Cicero, Arrigo F. G.
Fogacci, Federica
Stoian, Anca Pantea
Vrablik, Michal
Al Rasadi, Khalid
Banach, Maciej
Toth, Peter P.
Rizzo, Manfredi
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
title Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
title_full Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
title_fullStr Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
title_full_unstemmed Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
title_short Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
title_sort nutraceuticals in the management of dyslipidemia: which, when, and for whom? could nutraceuticals help low-risk individuals with non-optimal lipid levels?
topic Nonstatin Drugs (M. Vrablik, Section Editors)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332568/
https://www.ncbi.nlm.nih.gov/pubmed/34345932
http://dx.doi.org/10.1007/s11883-021-00955-y
work_keys_str_mv AT ciceroarrigofg nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT fogaccifederica nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT stoianancapantea nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT vrablikmichal nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT alrasadikhalid nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT banachmaciej nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT tothpeterp nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels
AT rizzomanfredi nutraceuticalsinthemanagementofdyslipidemiawhichwhenandforwhomcouldnutraceuticalshelplowriskindividualswithnonoptimallipidlevels

Ejemplares similares